Literature DB >> 15893738

Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons.

Manami Kimura1, Shigeru Akasofu, Hiroo Ogura, Kohei Sawada.   

Abstract

Donepezil, a potent acetylcholinesterase (AChE) inhibitor used for the treatment of Alzheimer's disease (AD), is thought to have a neuroprotective effect in AD patients. Because a deficit in cholinergic neurotransmission is a major feature in AD, and amyloid-beta (Abeta) accumulation has been proposed as a possible causative phenomenon, we were interested to examine the effect of donepezil on Abeta(1-40) induced neurotoxicity in primary cultures of rat septal neurons. Using immunohistochemical staining, almost all the neurons were found to be positive for vesicular acetylcholine transporter (VAChT) in these septal cultures. Septal neuronal cells were cultured for 7 days and then 15 micromol/L of Abeta(1-40) was added to the cell medium for 48 h. The cultured septal neurons were highly susceptible to Abeta toxicity, as shown by morphological examination and lactate dehydrogenase (LDH) assay. Donepezil concentration-dependently reduced the LDH efflux induced by Abeta(1-40), and the effect was significant at 100 nmol/L and above. Donepezil decreased both the negative peak at around 215 nm in the circular dichroism (CD) spectrum and the fluorescence intensity of thioflavin T in the presence of Abeta(1-40). These results suggest that donepezil exerts a neuroprotective effect by reducing the amount of the toxic form of Abeta fibrils in septal neuron cultures. These findings support the idea that the clinical efficacy of donepezil in AD is due to not only activation of cholinergic transmission, but also attenuation of neuronal damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893738     DOI: 10.1016/j.brainres.2005.04.014

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Donepezil in a narrow concentration range augments control and impaired by beta-amyloid peptide hippocampal LTP in NMDAR-independent manner.

Authors:  Nadezhda A Kapai; Julia V Bukanova; Elena I Solntseva; Vladimir G Skrebitsky
Journal:  Cell Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.046

Review 2.  Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?

Authors:  Ben Seltzer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 3.  Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

Authors:  Paul S Aisen; Jeffrey Cummings; Lon S Schneider
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

4.  The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor.

Authors:  J Meunier; J Ieni; T Maurice
Journal:  Br J Pharmacol       Date:  2006-10-23       Impact factor: 8.739

5.  The binding of donepezil with external mouth of K+-channels of molluscan neurons.

Authors:  Elena I Solntseva; Julia V Bukanova; Evgeny V Marchenko; Alexey V Rossokhin; Vladimir G Skrebitsky
Journal:  Cell Mol Neurobiol       Date:  2008-09-24       Impact factor: 5.046

Review 6.  Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.

Authors:  Seung Hyun Kim; Nagaendran Kandiah; Jung-Lung Hsu; Chuthamanee Suthisisang; Chesda Udommongkol; Amitabh Dash
Journal:  Br J Pharmacol       Date:  2017-10-29       Impact factor: 8.739

7.  On the inhibitory affect of some dementia drugs on DNA polymerase Beta activity.

Authors:  V N Vyjayanti; N S Chary; Kalluri Subba Rao
Journal:  Neurochem Res       Date:  2008-01-10       Impact factor: 3.996

8.  A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25-35-impaired mouse cognitive function.

Authors:  Zhengping Zhang; Rong Chen; Wenji An; Chunmei Wang; Gaoyong Liao; Xiaoliang Dong; Aijing Bi; Zhimin Yin; Lan Luo
Journal:  Psychopharmacology (Berl)       Date:  2015-11-11       Impact factor: 4.530

Review 9.  Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders.

Authors:  Roberta Benfante; Simona Di Lascio; Silvia Cardani; Diego Fornasari
Journal:  Aging Clin Exp Res       Date:  2019-10-03       Impact factor: 3.636

10.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.